Anas Younes • Bertrand Coiffier
Editors
2013
Over the past few years, our understanding of the molecular pathogenesis of malignant lymphomas has led to the improvement in the diagnostic precision and to the identification of a variety of molecular therapeutic targets. Furthermore, new drugs have been approved by the United States and European agencies, resulting in a change of the standard of care of several types of lymphoid malignancies. To provide a timely update on the most important advances in the biology, diagnosis, and therapy of lymphomas, we invited our internationally renowned colleagues to write 23 chapters covering clinically relevant topics. We hope that this book will provide valuable information to our readers.